Oral Antidiabetic Agent
-
Upload
rona-setiawati -
Category
Documents
-
view
234 -
download
1
Transcript of Oral Antidiabetic Agent
-
7/28/2019 Oral Antidiabetic Agent
1/24
Oral Antidiabetic Agent
-
7/28/2019 Oral Antidiabetic Agent
2/24
Oral Antidiabetic Agent
Consist of :
1. Insulin secretagogues
- Sulfonilureas- Meglitinide
- D-Phenylalanine derivatives : Nateglinide
2. Biguanides
3. Thiazolidinediones
4.-glucosidase inhibitors
-
7/28/2019 Oral Antidiabetic Agent
3/24
Insulin SecretagoguesA. Sulfonilureas
1. Increase insulin release from the pancreas
2. Reduce serum glucagon levels3. Closure of potassium channels in extrapancreatic
tissues > unknown clinical significance
-
7/28/2019 Oral Antidiabetic Agent
4/24
Ad.1. Increase insulin release from the pancrears
- Sulfonilureas bind to high-afinity sulfonilureareceptor
- The receptor of sulfonilurea is associated with B cell
- Inhibits the eff lux of potassium ions through the
channel depolarization opens a voltage-gated calcium channel calcium influx release ofpreformed insulin.
Ad.2. Reduce serum glucagon levels
- Mechanism for this suppressive effect on glucagonlevels is unclear.
- Probably it is caused by indirect inhibition due toenhanced release of both insulin and somatostatin
-
7/28/2019 Oral Antidiabetic Agent
5/24
Classification of sulfonilureas1. First generation of sulfonilureas
A. Tolbutamide
- Well absorbed
- Rapidly metabolized in the liver
- Its durations of effect is relatively short
- Elimination half-life is 4 5 hours
- Administered in divided doses
- The safest sulfonilurea for use in elderlydiabetic
- Several drugs : like dicumarol, phenylbutazone,some sulfonamides can inhibit the metabolism
of tolbutamide
-
7/28/2019 Oral Antidiabetic Agent
6/24
B. Chlorpropamide- Half life is 32 hours
- Slowly metabolized in the liver- Approximately 20 30% is excreted unchanged in the
urine- Interact with drugs that depend on hepatic oxidative
catabolism.
- Contra indicated in patients with hepatic or renalinsufficiency- Dosages in excess of 500 mg daily increase the risk of
jaundice- Prolonged hypoglycemic reactions are more common
in elderly patients (contraindication)- Side effects are : hyperemic flush after alcoholingestion in genetically predisposed patients,
dilutional hyponatremia, hematologictoxicity (transient leucopenia,thrombocytopenia)
-
7/28/2019 Oral Antidiabetic Agent
7/24
C. Tolazamide- More slowly absorbed than othersulfonilureas
- Half life is about 7 hours
- If more than 500 mg/d is required, the doseshould be divided and given twice daily
-
7/28/2019 Oral Antidiabetic Agent
8/24
2. Second-generation sulfonilureas
A. Glyburide- Metabolyzed in the liver into products with very lowhypoglycemic activity
- The usual starting dosage is 2,5 mg/d or less- The average maintenance dosage is 5 10 mg/d given
as a single morning dose- Maintenance dosage higher than 20 mg/d are not
recommended- A formulation of micronized glyburide is available
in a variety of tablet sizes- Adverse effect : Flushing after ethanol ingestion
(rarely)- Contraindicated in the presence of hepatic impairment
and renal insufficiency
-
7/28/2019 Oral Antidiabetic Agent
9/24
B. Glipizide
- Has the shortest half-life (2 4 hours)- Should be ingested 30 minutes beforebreakfast for maximum effect.
- The absorption is delayed when the drug is
taken with food- The starting dosage is 5 mg/d, with up to 15mg/d given as single dose.
- At least 90% of glipizide is metabolyzed in the
liver to inactive products, 10% is excretedunchanged in the urine.
- Contraindicated in patient with hepatic orrenal dysfunction.
-
7/28/2019 Oral Antidiabetic Agent
10/24
C. Glimepiride
- Approved for once daily use as monotherapy orin combination with insulin
- Maximal daily dose is 8 mg
- Half-life is 5 hours, long duration of effect
- Metabolyzed in liver
- Reduce blood glucose with the lowest dose ofany sulfonilureas compound.
-
7/28/2019 Oral Antidiabetic Agent
11/24
Secondary Failure of Sulfonilureas
- A progressive decrease in B cell mass
- Reduction in physical activity
- Decline in lean body mass
- Increase in ectopic fat deposition in chronic types 2diabetes.
-
7/28/2019 Oral Antidiabetic Agent
12/24
-
7/28/2019 Oral Antidiabetic Agent
13/24
B. Meglitinide- A new class of insulin secretagoues- Repaglinide
Has a very fast onset of action 1 hours Duration of action is 5 8 hours It is hepatically cleared by CYP3A4 Half life is 1 hour Indicated for use in controlling post prandial
glucose excursions Should be taken just before each meal in doses of
0,25 4 mg (maximum, 16 mg/d) Repaglinide is approved as monotherapy or in
combination with biguanides May be used in type 2 diabetic with sulfur or
sulfonilureas allergy
-
7/28/2019 Oral Antidiabetic Agent
14/24
C. D-PHENILALANINE DERIVATIVE
Nateglinide- Stimulates very rapid and transient release ofinsulin from B cells
- It partially restores initial insulin release in
reponse to IV glucose tolerance test- Indicated in patient with isolated post prandial
hyperglycemia
- Minimal effect on overnight or fasting glucose
level- It is efficacious when given alone or incombination with nonsecretagogues oral agent(such as metformin)
- Dose titration is not required.
-
7/28/2019 Oral Antidiabetic Agent
15/24
- It is ingested just prior to meals
- It is absorbed within 20 minutes after oraladministration
- Time to peak concentration is less than 1 hour
- It is hepatically metabolized by Cyp2cg andCyP3A4
- Half life is 1.5 hours
- The overall duration of action is less than 4
hours- Has the advantage of being safe in individual
with very reduced renal function
- Incidence of hypoglycemia is the lowest
-
7/28/2019 Oral Antidiabetic Agent
16/24
D. BIGUANIDES
- Structure of metformin is shown below
- Mechanism of action Direct stimulation of glycolysis in tissues with
increased glucose removal from blood Reduced hepatic and renal gluconeogenesis
Slowing of glucose absorption from the gastrointestinaltract, with increased glucose to lactate conversion byenterocytes
Reduction of Plasma glucagon levels
-
7/28/2019 Oral Antidiabetic Agent
17/24
Metabolisme and Excretion of metformin- Half life is 1,5 3 hours
- It is not bound to Plasma protein
- It is not metabolized- Metformin is excreted by the kidneys as the active
compound
- May impair the hepatic metabolism of lactic acid
- May increase the risk of lactic acidosis in patientwith renal insufficiency
-
7/28/2019 Oral Antidiabetic Agent
18/24
Clinical Use of metformin- Indication :
a. Patient with hyperglycemia due toineffective insulin action like insulinresistence syndrome
b. Use in combination with insulin secretagones intype 2 diabetes with inadequate oral
monotherapy
- Effective in preventing new onset of type 2diabetics in midde aged.
Obese individual with impaired glucose tolerance
-
7/28/2019 Oral Antidiabetic Agent
19/24
- Dosage is from 500 mg to a maximum 0f 2.25 gdaily
A common schedule would be to begin with asingle 500 mg tablet given with breakfast for
several days
If this is tolerated without GI discomfort andhyperglycemia persist 500 mg tablet may be
added with evening meal.
- Dosage should always be divided
- Adverse effect : Gastrointestinal discomfort
-
7/28/2019 Oral Antidiabetic Agent
20/24
Contraindication :- Renal disease
- Alcoholism- Hepatic disease
- Condition Predisposing to tissue anoxia
(Chronic cardiopulmonary disfunction)
-
7/28/2019 Oral Antidiabetic Agent
21/24
E. THIAZOLIDINEDIONES- Decrease insulin resistance- Major site of Tzd action is adipose tissue- Regulates adiposity apoptosis and differentiation- Two Tzd are : Pioglitazone and Rosiglitazone- Mechanism of action involves gene regulation
- Tzds are ligands of peroxisome proliferator activatedreceptor gamma (PPAR-)- Long term therapy is associated with a drop of Tryglyceride
level and a slight rise in HDL and LDL levels- Adverse effect is :
Fluid retention mild anemia peripheral edema (combination with insulin /
insulin secretagogues) Hepatotoxic
-
7/28/2019 Oral Antidiabetic Agent
22/24
F. ALPHA GLUCOSIDASE INHIBITORS- Competitive inhibitors of the intestinal - glucosidases- Reduce postprandial digestion and absorption of starch and
disaccharides lowering postmeal glycemic excursions as muchas 45 - 60 mg / dll- Consist of Acarbose and Miglitol- Therapy should be initiated with the lowest dose ; slowly titrated
upward- Adverse effect : flatulence (because undigested carbohydrate willbe fermented into short chain fattyacids releosinggas), diarrhea, abdominal pain- Contraindication :
Inflammatory bowel disease
Any intestinal condition that could be worsened by gas anddistention Patient with renal impairment Patient with hepatic disease
- Dosage of AGI : 25 100 mg before meals
-
7/28/2019 Oral Antidiabetic Agent
23/24
-
7/28/2019 Oral Antidiabetic Agent
24/24
THANK YOU